Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells

Endocrinology

Volumn 146, Issue 11, 2005, Pages 4951-4960

  Yeung, Ho Y ^a   Lai, Keng P ^a   Chan, Hoi Y ^a   Mak, Nai K ^a   Wagner, Graham F ^b   Wong, Chris K C ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COBALT CHLORIDE; DEFEROXAMINE; HYPOCALCIN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; MESSENGER RNA; OXYGEN; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; NASOPHARYNX CANCER; OVARY CANCER; PRIORITY JOURNAL; RNA INTERFERENCE;

ANOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DEFEROXAMINE; FEMALE; FERRIC COMPOUNDS; FERRICYANIDES; GLYCOPROTEINS; HUMANS; IRON CHELATING AGENTS; NASOPHARYNGEAL NEOPLASMS; NITRIC OXIDE DONORS; NITROPRUSSIDE; OVARIAN NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 26844510900     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-0365     Document Type: Article

References (62)

1. Wagner GF, Hampong M, Park CM, Copp DH 1986 Purification, characterization, and bioassay of teleocalcin, a glycoprotein from salmon corpuscles of Stannius. Gen Comp Endocrinol 63:481-491
2. Chang AC, Jeffrey KJ, Tokutake Y, Shimamoto A, Neumann AA, Dunham MA, Cha J, Sugawara M, Furuichi Y, Reddel RR 1998 Human stanniocalcin (STC): genomic structure, chromosomal localization, and the presence of CAG trinucleotide repeats. Genomics 47:393-398
3. Varghese R, Wong CK, Deol H, Wagner GF, DiMattia GE 1998 Comparative analysis of mammalian stanniocalcin genes. Endocrinology 139:4714-4725
4. Chang AC, Janosi J, Hulsbeek M, de Jong D, Jeffrey KJ, Noble JR, Reddel RR 1995 A novel human cDNA highly homologous to the fish hormone stanniocalcin. Mol Cell Endocrinol 112:241-247
5. Olsen HS, Cepeda MA, Zhang QQ, Rosen CA, Vozzolo BL 1996 Human stanniocalcin: a possible hormonal regulator of mineral metabolism. Proc Natl Acad Sci USA 93:1792-1796
6. Chang AC, Jellinek DA, Reddel RR 2003 Mammalian stanniocalcins and cancer. Endocr Relat Cancer 10:359-373
7. Ishibashi K, Imai M 2002 Prospect of a stanniocalcin endocrine/paracrine system in mammals. Am J Physiol Renal Physiol 282:F367-F375
8. Filvaroff EH, Guillet S, Zlot C, Bao M, Ingle G, Steinmetz H, Hoeffel J, Bunting S, Ross J, Carano RA, Powell-Braxton L, Wagner GF, Eckert R, Gerritsen ME, French DM 2002 Stanniocalcin 1 alters muscle and bone structure and function in transgenic mice. Endocrinology 143:3681-3690
9. Varghese R, Gagliardi AD, Bialek PE, Yee SP, Wagner GF, DiMattia GE 2002 Overexpression of human stanniocalcin affects growth and reproduction in transgenic mice. Endocrinology 143:868-876
10. McCudden CR, James KA, Hasilo C, Wagner GF 2002 Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism. J Biol Chem 277:45249-45258
11. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T, Nakamura Y 1993 Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 53:1172-1174
12. Fujiwara Y, Monden M, Mori T, Nakamura Y, Emi M 1993 Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res 53:857-860
13. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, Faber PW, Bosman FT 1994 Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54:6061-6064
14. Kagan J, Stein J, Babaian RJ, Joe YS, Pisters LL, Glassman AB, von Eschenbach AC, Troncoso P 1995 Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11:2121-2126
15. Takle LA, Knowles MA 1996 Deletion mapping implicates two tumor suppressor genes on chromosome 8p in the development of bladder cancer. Oncogene 12:1083-1087
16. Fujiwara Y, Sugita Y, Nakamori S, Miyamoto A, Shiozaki K, Nagano H, Sakon M, Monden M 2000 Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers. Int J Oncol 16:799-804
17. Gerritsen ME, Soriano R, Yang S, Ingle G, Zlot C, Toy K, Winer J, Draksharapu A, Peale F, Wu TD, Williams PM 2002 In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. Physiol Genomics 10:13-20
18. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y 2001 Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61:2129-2137
19. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T, Murakumo Y, Murakami H, Sugiura H, Iwata H, Ishiguro N, Takahashi M 2002 Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161:249-256
20. McCudden CR, Majewski A, Chakrabarti S, Wagner GF 2004 Co-localization of stanniocalcin-1 ligand and receptor in human breast carcinomas. Mol Cell Endocrinol 213:167-172
21. Welcsh PL, Lee MK, Gonzalez-Hernandez RM, Black DJ, Mahadevappa M, Swisher EM, Warrington JA, King MC 2002 BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 99:7560-7565
22. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE, Venter DJ 2002 Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62:1289-1295
23. Kahn J, Mehraban F, Ingle G, Xin X, Bryant JE, Vehar G, Schoenfeld J, Grimaldi CJ, Peale F, Draksharapu A, Lewin DA, Gerritsen ME 2000 Gene expression profiling in an in vitro model of angiogenesis. Am J Pathol 156:1887-1900
24. Ismail RS, Baldwin RL, Fang J, Browning D, Karlan BY, Gasson JC, Chang DD 2000 Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res 60:6744-6749
25. Liang P, Averboukh L, Keyomarsi K, Sager R, Pardee AB 1992 Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. Cancer Res 52:6966-6968
26. Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, Davis GE 2001 Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 114:2755-2773
27. Liu D, Jia H, Holmes DI, Stannard A, Zachary I 2003 Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler Thromb Vasc Biol 23:2002-2007
28. Wary KK, Thakker GD, Humtsoe JO, Yang J 2003 Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer 2:25
29. Wascher RA, Huynh KT, Giuliano AE, Hansen NM, Singer FR, Elashoff D, Hoon DS 2003 Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 9:1427-1435
30. 2-regulated prolyl hydroxylation. Science 292:468-472
31. Kraggerud SM, Sandvik JA, Pettersen EO 1995 Regulation of protein synthesis in human cells exposed to extreme hypoxia. Anticancer Res 15:683-686
32. Pettersen EO, Juul NO, Ronning OW 1986 Regulation of protein metabolism of human cells during and after acute hypoxia. Cancer Res 46:4346-4351
33. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987-7992
34. Maxwell PH, Wiesener MS, Chang GW,Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ 1999 The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
35. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L, Trepel J, Montuenga LM, Ryan H, Johnson R, Gassmann M, Cuttitta F 2000 Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 14:848-862
36. Le NT, Richardson DR 2004 Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104:2967-2975
37. Chaston TB, Lovejoy DB, Watts RN, Richardson DR 2003 Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9:402-414
38. Cooper CE, Lynagh GR, Hoyes KP, Hider RC, Cammack R, Porter JB 1996 The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem 271:20291-20299
39. Liang SX, Richardson DR 2003 The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis 24:1601-1614
40. Sogawa K, Numayama-Tsuruta K, Ema M, Abe M, Abe H, Fujii-Kuriyama Y 1998 Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc Natl Acad Sci USA 95:7368-7373
41. Cadenas E, Poderoso JJ, Antunes F, Boveris A 2001 Analysis of the pathways of nitric oxide utilization in mitochondria. Free Radic Res 33:747-756
42. Chen W, Jin W, Tian H, Sicurello P, Frank M, Orenstein JM, Wahl SM 2001 Requirement for transforming growth factor β1 in controlling T cell apoptosis. J Exp Med 194:439-453
43. Wrutniak-Cabello C, Casas F, Cabello G 2001 Thyroid hormone action in mitochondria. J Mol Endocrinol 26:67-77
44. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Ratcliffe PJ 1997 Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 94:8104-8109
45. 2 tension. Proc Natl Acad Sci USA 92:5510-5514
46. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, Dillehay LE, Madan A, Semenza GL, Bedi A 2000 Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev 14:34-44
47. Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M 2001 Constitutive expression of hypoxia-inducible factor-1α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61:6548-6554
48. Jiang BH, Agani F, Passaniti A, Semenza GL 1997 V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328-5335
49. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E 1998 Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490
50. Lal A, Peters H, St. Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, van der Kogel AJ, Riggins GJ 2001 Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337-1343
51. Zhang K, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS, Andersson LC 2000 Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci USA 97:3637-3642
52. Eisenhofer G, Huynh TT, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS, Elkahloun AG 2004 Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel Lindau syndrome. Endocr Relat Cancer 11:897-911
53. Ito D, Walker JR, Thompson CS, Moroz I, Lin W, Veselits ML, Hakim AM, Fienberg AA, Thinakaran G 2004 Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol Cell Biol 24:9456-9469
54. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL 2005 Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659-669
55. Giatromanolaki A, Sivridis E, Koukourakis MI 2004 Tumour angiogenesis: vascular growth and survival. APMIS 112:431-440
56. Schmitt O, Schubert C, Feyerabend T, Hellwig-Burgel T, Weiss C, Kuhnel W 2002 Preferential topography of proteins regulating vascularization and apoptosis in a MX1 xenotransplant after treatment with hypoxia, hyperthermia, ifosfamide, and irradiation. Am J Clin Oncol 25:325-336
57. Hopfl G, Wenger RH, Ziegler U, Stallmach T, Gardelle O, Achermann R, Wergin M, Kaser-Hotz B, Saunders HM, Williams KJ, Stratford IJ, Gassmann M, Desbaillets I 2002 Rescue of hypoxia-inducible factor-1α-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res 62:2962-2970
58. Le NT, Richardson DR 2002 The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603:31-46
59. Richardson DR 2001 The controversial role of deferiprone in the treatment of thalassemia. J Lab Clin Med 137:324-329
60. Richardson DR, Ponka P 1998 Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131:306-315
61. Darnell G, Richardson DR 1999 The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94:781-792
62. 1 phase of the cell cycle. Cancer Res 53:3968-3975